Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT00332241
PHASE3

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

View on ClinicalTrials.gov

Summary

This study will compare the effectiveness (how well the drug works) of aripiprazole, flexibly dosed with a placebo, in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).

Official title: A Multicenter Double-Blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Key Details

Gender

All

Age Range

6 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

98

Start Date

2006-06-01

Completion Date

2008-04-01

Last Updated

2026-05-13

Healthy Volunteers

No

Interventions

DRUG

Aripiprazole

Tablets, Oral, 5, 10, or 15 mg, once daily, 8 weeks

DRUG

Placebo

Tablets, Oral, once daily, 8 weeks

Locations (9)

Marsella, Gregory

Boca Raton, Florida, United States

Child Neurology Associates, Pc

Atlanta, Georgia, United States

University Of Louisville

Louisville, Kentucky, United States

Neurobehavioral Medicine Group

Bloomfield Hills, Michigan, United States

Center For Psychiatry And Behavioral Medicine

Las Vegas, Nevada, United States

Suny - Stony Brook School Of Medicine

Stony Brook, New York, United States

Univ Of Nc

Chapel Hill, North Carolina, United States

Ut Medical Group

Memphis, Tennessee, United States

Red Oak Psychiatry Associates, Pa

Houston, Texas, United States